Artia Global Partners LP — 13F Holdings & Portfolio
CIK 1937964 · latest 13F-HR filed 2026-08-14
Artia Global Partners LP manages $541.9M in 13F-reported U.S. long-equity assets across 48 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are ABVX (12.70%), INSM (11.59%), TRVI (7.61%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 7 new positions and exited 8; 27 existing positions rose in reported value and 3 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 66.5%Cumulative share of the portfolio held in the largest N positions.
STE 2120
MIAMI, FL 33131
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| ARTIA GLOBAL PARTNERS GP LLC Control | GENERAL PARTNER | Less than 5% | Domestic Entity |
| CHANTANAPONGWANIJ, ONUSA, NMN Control | MANAGING PARTNER | 75% or more | Individual |
| CHANTANAPONGWANIJ, ONUSA, NMN Control | MANAGING MEMBER | 75% or more | Individual |
| VERDI, WILLIAM, CHRISTOPHER Control | CHIEF COMPLIANCE OFFICER AND CHIEF FINANCIAL OFFICER | Less than 5% | Individual |
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- BRIGHTSPRING HEALTH SVCS INC$33.8M +1473.8%
- REVOLUTION MEDICINES INC$22.6M +185.6%
- TREVI THERAPEUTICS INC$17.2M +71.6%
- TRAVERE THERAPEUTICS INC$17.2M +816.9%
- ARGENX SE$5.9M +27.0%
Top Trims
- INSMED INC-$40.0M -38.9%
- UNITED THERAPEUTICS CORP DEL-$255.8K -8.6%
- TENAX THERAPEUTICS INC-$60.6K -9.0%
New Positions
- ALKERMES PLC$23.5M
- GUARDANT HEALTH INC$5.7M
- ABSCI CORPORATION$5.4M
- ASCENDIS PHARMA A/S$4.7M
- ORUKA THERAPEUTICS INC$3.2M
Exited Positions
- ELI LILLY & CO$35.2M
- TERNS PHARMACEUTICALS INC$5.5M
- ASCENDIS PHARMA A/S$4.1M
- ABBVIE INC$3.2M
- SOLENO THERAPEUTICS INC$2.3M
Artia Global Partners LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | ABIVAX SA | ABVX | 00370M103 | $68.8M | 12.70% | 516,447 | SH |
| 2 | INSMED INC | INSM | 457669307 | $62.8M | 11.59% | 589,052 | SH |
| 3 | TREVI THERAPEUTICS INC | TRVI | 89532M101 | $41.2M | 7.61% | 2,210,852 | SH |
| 4 | BRIGHTSPRING HEALTH SVCS INC | BTSG | 10950A106 | $36.1M | 6.66% | 517,315 | SH |
| 5 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $34.7M | 6.41% | 185,390 | SH |
| 6 | ARGENX SE | ARGX | 04016X101 | $27.6M | 5.09% | 29,739 | SH |
| 7 | ALKERMES PLC | ALKS | G01767105 | $23.5M | 4.34% | 448,964 | SH |
| 8 | TRAVERE THERAPEUTICS INC | TVTX | 89422G107 | $19.3M | 3.55% | 339,033 | SH |
| 9 | ASTRAZENECA PLC | AZN | G0593M107 | $18.7M | 3.44% | 98,376 | SH |
| 10 | NEWAMSTERDAM PHARMA COMPANY | NAMS | N62509109 | $17.1M | 3.15% | 503,936 | SH |
| 11 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $15.9M | 2.93% | 162,990 | SH |
| 12 | SPDR SERIES TRUST Put | XBI | 78464A870 | $15.8M | 2.92% | 100,000 | SH |
| 13 | QUEST DIAGNOSTICS INC | DGX | 74834L100 | $13.8M | 2.55% | 65,122 | SH |
| 14 | IONIS PHARMACEUTICALS INC | IONS | 462222100 | $11.4M | 2.11% | 144,376 | SH |
| 15 | EYEPOINT INC | EYPT | 30233G209 | $11.0M | 2.02% | 767,098 | SH |
| 16 | ALUMIS INC | ALMS | 022307102 | $7.8M | 1.45% | 278,546 | SH |
| 17 | VIKING THERAPEUTICS INC | VKTX | 92686J106 | $7.1M | 1.30% | 180,731 | SH |
| 18 | CELCUITY INC | CELC | 15102K100 | $6.2M | 1.15% | 59,316 | SH |
| 19 | CYTOKINETICS INC | CYTK | 23282W605 | $6.0M | 1.11% | 70,700 | SH |
| 20 | MERCK & CO INC | MRK | 58933Y105 | $6.0M | 1.11% | 46,700 | SH |
| 21 | RAPPORT THERAPEUTICS INC | RAPP | 75383L102 | $5.8M | 1.07% | 138,508 | SH |
| 22 | JOHNSON & JOHNSON | JNJ | 478160104 | $5.7M | 1.06% | 22,600 | SH |
| 23 | GUARDANT HEALTH INC | GH | 40131M109 | $5.7M | 1.05% | 38,100 | SH |
| 24 | ABSCI CORPORATION | ABSI | 00091E109 | $5.4M | 0.99% | 464,444 | SH |
| 25 | SCHOLAR ROCK HLDG CORP | SRRK | 80706P103 | $5.3M | 0.98% | 96,285 | SH |
| 26 | SIONNA THERAPEUTICS INC | SION | 829401108 | $5.3M | 0.97% | 119,741 | SH |
| 27 | ASCENDIS PHARMA A/S | ASND | K08588103 | $4.7M | 0.87% | 17,740 | SH |
| 28 | ROIVANT SCIENCES LTD | ROIV | G76279101 | $4.6M | 0.85% | 129,800 | SH |
| 29 | PALISADE BIO INC | PALI | 696389402 | $4.2M | 0.77% | 1,992,367 | SH |
| 30 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $4.0M | 0.74% | 98,800 | SH |
| 31 | BIOGEN INC | BIIB | 09062X103 | $4.0M | 0.74% | 18,437 | SH |
| 32 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $3.9M | 0.72% | 65,000 | SH |
| 33 | BELITE BIO INC | BLTE | 07782B104 | $3.8M | 0.71% | 24,989 | SH |
| 34 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $3.7M | 0.69% | 137,800 | SH |
| 35 | PROKIDNEY CORP | PROK | 74291D104 | $3.7M | 0.68% | 1,806,939 | SH |
| 36 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $3.7M | 0.68% | 72,100 | SH |
| 37 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $3.2M | 0.59% | 33,400 | SH |
| 38 | PROTAGONIST THERAPEUTICS INC | PTGX | 74366E102 | $2.8M | 0.52% | 22,951 | SH |
| 39 | UNITED THERAPEUTICS CORP DEL | UTHR | 91307C102 | $2.7M | 0.50% | 5,000 | SH |
| 40 | BRIGHT MINDS BIOSCIENCES INC | DRUG | 10919W405 | $2.7M | 0.50% | 38,407 | SH |
| 41 | KINIKSA PHARMACEUTICALS INTL | KNSA | G52694109 | $1.9M | 0.34% | 29,200 | SH |
| 42 | COMPASS THERAPEUTICS INC | CMPX | 20454B104 | $839.2K | 0.15% | 383,200 | SH |
| 43 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $837.0K | 0.15% | 2,500 | SH |
| 44 | KODIAK SCIENCES INC | KOD | 50015M109 | $663.1K | 0.12% | 17,019 | SH |
| 45 | TENAX THERAPEUTICS INC | TENX | 88032L605 | $612.3K | 0.11% | 42,080 | SH |
| 46 | NUVALENT INC | NUVL | 670703107 | $605.1K | 0.11% | 4,900 | SH |
| 47 | PEPGEN INC | PEPG | 713317105 | $369.6K | 0.07% | 205,324 | SH |
| 48 | SPYRE THERAPEUTICS INC | SYRE | 00773J202 | $355.1K | 0.07% | 4,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $541.9M | 48 | 0001937964-26-000008 |
| 2026-03-31 | 2026-05-15 | $499.4M | 50 | 0001937964-26-000007 |
| 2025-12-31 | 2026-02-17 | $705.8M | 55 | 0001937964-26-000002 |
| 2025-09-30 | 2025-11-14 | $630.9M | 51 | 0001937964-25-000009 |
STE 2120
MIAMI, FL 33131